Skip to main content
OpenTrials

Clinical trial condition

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Explore clinical trials studying Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Study availability and eligibility vary by location and protocol.

294 public trials 62 recruiting studies
Refine in advanced search Browse all conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma trial results

Active, Not Recruiting

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT05602194

Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, +26 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 228 locations
View Trial Details
Active, Not Recruiting

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

NCT03504644

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +29 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 170 locations
View Trial Details
Active, Not Recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

NCT00792948

Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, +26 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
View all 157 locations
View Trial Details
Active, Not Recruiting

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

NCT02112916

Conditions
Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, +17 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
View all 212 locations
View Trial Details
Active, Not Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT03007147

Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Burkitt Lymphoma, +24 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • USA Health Strada Patient Care Center Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
View all 226 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

NCT06035497

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +26 more
Locations
  • Local Institution - 0031 Anjo-shi, Aichi-ken, Japan
  • Local Institution - 0011 Nagoya, Aichi-ken, Japan
  • Local Institution - 0024 Toyohashi, Aichi-ken, Japan
  • Local Institution - 0017 Kamogawa, Chiba, Japan
View all 40 locations
View Trial Details

Related conditions